2024/08/06 21:59:33 | |
---|---|
Price | |
0.75 USD | |
Difference | -1.19% (-0.01) |
ISIN | NL0010391025 |
Symbol | PHARM |
Exchange | FINRA other OTC Issues |
Currency | USD |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 487 EUR |
Benchmark | AMSTERDAM EXCHANGES INDEX |
Bid (Bid size) | - |
Ask (Ask size) | - |
Open | 0.75 USD |
High | 0.75 USD |
Low | 0.75 USD |
Close (prev. day) | 0.759 USD |
VWAP | 0.75 USD |
Volume (pcs) | 769 |
Trading volume | 576.75 |
Number of trades | 1 |
Last size | 769 |
Related Futures | - |
Related Options | - |
Date | Headline | Download | |
2024/07/24 | Global Equity Ratings | ||
2024/07/12 | Global Equity Ratings | ||
2024/06/21 | Global Equity Ratings | ||
2024/06/14 | Global Equity Ratings | ||
2024/05/29 | Global Equity Ratings |
2024/08/06 21:59:33 | |
---|---|
Price | |
0.75 USD | |
Difference | -1.19% (-0.01) |
ISIN | NL0010391025 |
Symbol | PHARM |
Exchange | FINRA other OTC Issues |
Currency | USD |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 487 EUR |
Benchmark | AMSTERDAM EXCHANGES INDEX |
Bid (Bid size) | - |
Ask (Ask size) | - |
Open | 0.75 USD |
High | 0.75 USD |
Low | 0.75 USD |
Close (prev. day) | 0.759 USD |
VWAP | 0.75 USD |
Volume (pcs) | 769 |
Trading volume | 576.75 |
Number of trades | 1 |
Last size | 769 |
6m | 1Y | 3Y | |
Perf (%) | -41.86% | -39.52% | -34.78% |
Perf (abs.) | -0.54 | -0.49 | -0.40 |
Beta | 1.29 | 0.98 | 0.82 |
Volatility | 91.53 | 93.71 | 92.85 |
Ø price 5 days | Ø volume 5 days (pcs.) | 0.77 USD (4,400) |
Ø price 30 days | Ø volume 30 days (pcs.) | 0.80 USD (1,737) |
Ø price 100 days | Ø volume 100 days (pcs.) | 0.86 USD (600) |
Ø price 250 days | Ø volume 250 days (pcs.) | 1.03 USD (1,087) |
YTD High | date | 1.29 USD (2024/01/30) |
YTD Low | date | 0.75 USD (2024/07/29) |
52 Weeks High | date | 1.40 USD (2023/09/21) |
52 Weeks Low | date | 0.75 USD (2024/07/29) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Tradegate | 2024/08/07 | 10:00 | 0.73 EUR | 0.01 | 10 |
Stuttgart | 2024/08/07 | 12:25 | 0.7305 EUR | 0.00 | 5 |
Munich | 2024/08/07 | 08:18 | 0.702 EUR | 0.00 | 1 |
London Stock Exchange European Trade Reporting | 2024/08/07 | 08:59 | 0.729 EUR | 0.00 | 1 |
Frankfurt | 2024/08/07 | 08:08 | 0.71 EUR | 0.00 | 1 |
FINRA other OTC Issues | 2024/08/06 | 21:59 | 0.75 USD | 0.00 | 1 |
Euronext Amsterdam | 2024/08/07 | 13:01 | 0.7315 EUR | 1.49 | 576 |
Duesseldorf | 2024/08/07 | 08:10 | 0.7025 EUR | 0.00 | 1 |
Berlin | 2024/08/07 | 08:18 | 0.7035 EUR | 0.00 | 1 |
PHARMING GROUP NV |
- - |
Darwinweg 24 - 2333 CR Leiden |
Telefon: +31-71-524-74-00 |
Fax: + |
E-mail: info@pharming.com |
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following segments: RUCONEST®, Joenja®, Europe, and Rest of the World. The company was founded on November 11, 1988, and is headquartered in Leiden, the Netherlands. |
Sijmen de Vries | Chairman of Managing Board |
Alexander Breidenbach | Member of Executive Committee |
Anurag Relan | Member of Executive Committee |
Jeroen Wakkerman | Member of Executive Committee |
Mireille Sanders | Member of Executive Committee |
Ruud van Outersterp | Member of Executive Committee |
Stephen Toor | Member of Executive Committee |
Richard Peters | Chairman of Supervisory Board |
Jabine T. M. van der Meijs | Member of Supervisory Board |
Mark Pykett | Member of Supervisory Board |
Barbara Yanni | Member of Supervisory Board |
Deborah Jorn | Member of Supervisory Board |
Leonard Kruimer | Member of Supervisory Board |
Steven Baert | Member of Supervisory Board |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer